Pfizer appoints management changes to take effect in 2014.
Pfizer has named Albert Bourla as group president of the company’s Vaccines, Oncology and Consumer Healthcare business and Susan Silbermann as president and general manager, Global Vaccines business, both effective Jan. 1, 2014.
Doug Lankler, who was to become general counsel on January 1, and Rady Johnson who was to become chief compliance and risk officer on January 1, both assume their new positions immediately.
On January 1, the company will begin operating with three commercial businesses-the Global Innovative Pharmaceutical business, led by Geno Germano, the Global Established Pharmaceutical business, led by John Young, and the Vaccines, Oncology, and Consumer Healthcare business led by Albert Bourla.
